JP2024514339A5 - - Google Patents
Info
- Publication number
- JP2024514339A5 JP2024514339A5 JP2023564025A JP2023564025A JP2024514339A5 JP 2024514339 A5 JP2024514339 A5 JP 2024514339A5 JP 2023564025 A JP2023564025 A JP 2023564025A JP 2023564025 A JP2023564025 A JP 2023564025A JP 2024514339 A5 JP2024514339 A5 JP 2024514339A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- membered
- heteroatoms selected
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175974P | 2021-04-16 | 2021-04-16 | |
| US63/175,974 | 2021-04-16 | ||
| US202163281493P | 2021-11-19 | 2021-11-19 | |
| US63/281,493 | 2021-11-19 | ||
| PCT/US2022/025083 WO2022221704A1 (en) | 2021-04-16 | 2022-04-15 | Compounds, compositions and methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514339A JP2024514339A (ja) | 2024-04-01 |
| JP2024514339A5 true JP2024514339A5 (cg-RX-API-DMAC7.html) | 2026-06-24 |
Family
ID=81580947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564025A Pending JP2024514339A (ja) | 2021-04-16 | 2022-04-15 | がんを治療する化合物、組成物、及び方法 |
Country Status (14)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4359381A4 (en) * | 2021-06-21 | 2025-04-30 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| US20250042896A1 (en) * | 2021-10-29 | 2025-02-06 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Polycyclic compound as cbl-b inhibitor |
| US12187709B2 (en) | 2021-11-05 | 2025-01-07 | Genentech, Inc. | Lactams as CBL-B inhibitors selective over C-CBL |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| WO2023250097A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| JP2025523682A (ja) * | 2022-07-12 | 2025-07-23 | ホットスポット セラピューティクス インコーポレイテッド | 複素環式化合物の調製方法 |
| KR20250085707A (ko) * | 2022-07-12 | 2025-06-12 | 핫스팟 세라퓨틱스, 인크. | Cbl-b 조절제로서의 트리아진 유도체의 고체 형태 |
| JP2025523058A (ja) * | 2022-07-12 | 2025-07-17 | ホットスポット セラピューティクス インコーポレイテッド | Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置 |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
| CN119630662A (zh) * | 2022-07-18 | 2025-03-14 | 英矽智能科技知识产权有限公司 | Cbl-b抑制剂及其应用方法 |
| WO2024077244A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024077236A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024086730A1 (en) * | 2022-10-19 | 2024-04-25 | Hotspot Therapeutics, Inc. | Heterocyclic cbl-b inhibitors for the treatment of cancer |
| US20260193251A1 (en) | 2022-11-16 | 2026-07-09 | Pfizer Inc. | Substituted Bicyclic Pyridone Derivatives |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| EP4653436A1 (en) * | 2023-01-19 | 2025-11-26 | Guangzhou Yufan Nantu Biotechnologies Co., Ltd | Heterocyclic compounds, preparation method therefor and use thereof |
| WO2024153246A1 (zh) * | 2023-01-20 | 2024-07-25 | 海南先声再明医药股份有限公司 | 取代的三环化合物及其应用 |
| WO2024227436A1 (en) * | 2023-05-04 | 2024-11-07 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025067342A1 (zh) * | 2023-09-27 | 2025-04-03 | 北京望实智慧科技有限公司 | 用作Cbl-b抑制剂的化合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740837A1 (de) * | 1987-11-27 | 1989-06-08 | Schering Ag | Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel |
| BRPI0814441A2 (pt) * | 2007-07-19 | 2015-07-14 | Schering Corp | Compostos de amida heterocíclica como inibidores de proteína cinase |
| KR20100072266A (ko) * | 2007-10-24 | 2010-06-30 | 머크 샤프 앤드 돔 코포레이션 | 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제 |
| US10968216B2 (en) * | 2016-10-27 | 2021-04-06 | Bayer Aktiengesellschaft | 4,5-annulated 1,2,4-triazolones |
| EP3573971A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3733667B1 (en) * | 2017-12-26 | 2024-06-12 | Sumitomo Chemical Company, Limited | Heterocyclic compounds and noxious arthropod control agent containing same |
| KR102922115B1 (ko) * | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| CA3294689A1 (en) * | 2019-06-26 | 2026-03-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| JP2020169215A (ja) * | 2020-07-15 | 2020-10-15 | 住友化学株式会社 | 複素環化合物を用いる有害節足動物防除方法 |
| IL301690A (en) * | 2020-10-16 | 2023-05-01 | Dana Farber Cancer Inst Inc | Piperidinyl small molecule degraders of helios and methods of use |
| KR20250085707A (ko) * | 2022-07-12 | 2025-06-12 | 핫스팟 세라퓨틱스, 인크. | Cbl-b 조절제로서의 트리아진 유도체의 고체 형태 |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
| JP2025523682A (ja) * | 2022-07-12 | 2025-07-23 | ホットスポット セラピューティクス インコーポレイテッド | 複素環式化合物の調製方法 |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| JP2025523058A (ja) * | 2022-07-12 | 2025-07-17 | ホットスポット セラピューティクス インコーポレイテッド | Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置 |
-
2022
- 2022-04-15 US US18/286,966 patent/US20240228482A1/en active Pending
- 2022-04-15 TW TW111114558A patent/TW202309023A/zh unknown
- 2022-04-15 CA CA3215395A patent/CA3215395A1/en active Pending
- 2022-04-15 WO PCT/US2022/025083 patent/WO2022221704A1/en not_active Ceased
- 2022-04-15 MX MX2023012245A patent/MX2023012245A/es unknown
- 2022-04-15 PE PE2023002860A patent/PE20240767A1/es unknown
- 2022-04-15 JP JP2023564025A patent/JP2024514339A/ja active Pending
- 2022-04-15 KR KR1020237039416A patent/KR20240037184A/ko active Pending
- 2022-04-15 IL IL307732A patent/IL307732A/en unknown
- 2022-04-15 AU AU2022256514A patent/AU2022256514A1/en active Pending
- 2022-04-15 BR BR112023021068A patent/BR112023021068A2/pt unknown
- 2022-04-15 EP EP22721591.0A patent/EP4323358A1/en active Pending
-
2023
- 2023-10-13 CL CL2023003068A patent/CL2023003068A1/es unknown
- 2023-11-16 CO CONC2023/0015484A patent/CO2023015484A2/es unknown